Aupetit J F, Bui-Xuan B, Kioueh I, Loufoua J, Frassati D, Timour Q
Department of Cardiology, St. Joseph and St. Luc Hospital, Lyon, France.
Can J Physiol Pharmacol. 2000 Mar;78(3):208-16.
It is known that class I antiarrhythmic drugs lose their antifibrillatory activity with severe ischaemia, whereas class IV antiarrhythmic drugs acquire such activity. Tachycardia, which is also a depolarizing factor, has recently been shown to give rise to an alteration of ion transmembrane exchanges which is particularly marked in the case of calcium. This leads one to wonder if the change in antifibrillatory activity of antiarrhythmic drugs caused by ischaemia depends on the same process. The change in antifibrillatory activity was studied in normal conditions ranging to those of severe ischaemia with a class I antiarrhythmic drug, flecainide (1.00 mg x kg(-1) plus 0.04 mg x kg(-1)x min(-1), a sodium channel blocker, and a class IV antiarrhythmic drug, verapamil (50 microg x kg(-1) plus 2 microg x kg(-1) x min(-1)), a calcium channel blocker. The experiments were performed in anaesthetized, open-chest pigs. The resulting blockade of each of these channels was assessed at the end of ischaemic periods of increasing duration (30, 60, 120, 180, 300, and 420 s) by determining the ventricular fibrillation threshold (VFT). VFT was determined by means of trains of diastolic stimuli of 100 ms duration delivered by a subepicardial electrode introduced into the myocardium (heart rate 180 beats per min). Ischaemia was induced by completely occluding the left anterior descending coronary artery. The monophasic action potential was recorded concurrently for the measurement of ventricular conduction time (VCT). The monophasic action potential duration (MAPD) varied with membrane polarization of the fibres. The blockade of sodium channels by flecainide, which normally raises VFT (7.0 +/- 0.4 to 13.8 +/- 0.8 mA, p < 0.001) and lengthens VCT (28 +/- 3 to 44 +/- 5 ms, p < 0.001), lost its effects in the course of ischaemia. This resulted in decreased counteraction of the ischaemia-induced fall of VFT and decreased aggravation of the ischaemia-induced lengthening of VCT. The blockade of calcium channels, which normally does not alter VFT (between 7.2 +/- 0.6 and 8.4 +/- 0.7 mA, n.s.) or VCT (between 30 +/- 2 and 34 +/- 3 ms, n.s.), slowed the ischaemia-induced fall of VFT. VFT required more time to reach 0 mA, thus delaying the onset of fibrillation. Membrane depolarization itself was opposed as the shortening of MAPD and the lengthening of VCT were also delayed. Consequently there is a progressive decrease in the role played by sodium channels during ischaemia in the rhythmic systolic depolarization of the ventricular fibres. This reduces or suppresses the ability of sodium channel blockers to act on excitability or conduction, and increases the role of calcium channel blockers in attenuating ischaemia-induced disorders.
已知I类抗心律失常药物在严重缺血时会失去其抗纤颤活性,而IV类抗心律失常药物则会获得这种活性。心动过速也是一种去极化因素,最近已被证明会引起离子跨膜交换的改变,这在钙的情况下尤为明显。这使人不禁要问,缺血引起的抗心律失常药物抗纤颤活性的变化是否取决于相同的过程。使用I类抗心律失常药物氟卡尼(1.00 mg·kg⁻¹加0.04 mg·kg⁻¹·min⁻¹,一种钠通道阻滞剂)和IV类抗心律失常药物维拉帕米(50 μg·kg⁻¹加2 μg·kg⁻¹·min⁻¹,一种钙通道阻滞剂),在从正常状态到严重缺血的条件下研究了抗纤颤活性的变化。实验在麻醉的开胸猪身上进行。在缺血时间逐渐增加(30、60、120、180、300和420秒)结束时,通过测定心室颤动阈值(VFT)来评估对这些通道中每一个的阻断情况。VFT通过插入心肌的心外膜下电极给予持续100毫秒的舒张期刺激序列来测定(心率180次/分钟)。通过完全阻断左前降支冠状动脉诱导缺血。同时记录单相动作电位以测量心室传导时间(VCT)。单相动作电位持续时间(MAPD)随纤维膜极化而变化。氟卡尼对钠通道的阻断通常会提高VFT(从7.0±0.4到13.8±0.8 mA,p<0.001)并延长VCT(从28±3到44±5毫秒,p<0.001),但在缺血过程中失去了这些作用。这导致对缺血诱导的VFT下降的对抗作用减弱,以及对缺血诱导的VCT延长的加重作用减弱。钙通道的阻断通常不会改变VFT(在7.2±0.6和